State Street
EIGR

State Street’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

State Street’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,893
Closed -$33K – 4419
2023
Q4 		$33K Hold
4,893
– – ﹤0.01% 4267
2023
Q3 		$44.8K Hold
4,893
– – ﹤0.01% 4314
2023
Q2 		$103K Sell
4,893
-23,007
-82% -$709K ﹤0.01% 4230
2023
Q1 		$751K Buy
27,900
+917
+3% +$42.7K ﹤0.01% 3618
2022
Q4 		$955K Buy
26,983
+213
+0.8% +$25.6K ﹤0.01% 3570
2022
Q3 		$6.05M Buy
26,770
+3,358
+14% +$825K ﹤0.01% 2964
2022
Q2 		$4.42M Buy
23,412
+4,935
+27% +$995K ﹤0.01% 3155
2022
Q1 		$4.6M Buy
18,477
+272
+1% +$43K ﹤0.01% 3223
2021
Q4 		$2.83M Sell
18,205
-318
-2% -$61.5K ﹤0.01% 3519
2021
Q3 		$3.71M Buy
18,523
+470
+3% +$112K ﹤0.01% 3387
2021
Q2 		$4.61M Buy
18,053
+1,041
+6% +$260K ﹤0.01% 3291
2021
Q1 		$4.52M Buy
17,012
+420
+3% +$132K ﹤0.01% 3093
2020
Q4 		$6.12M Buy
16,592
+1,178
+8% +$338K ﹤0.01% 2867
2020
Q3 		$3.76M Buy
15,414
+85
+0.6% +$26.4K ﹤0.01% 2924
2020
Q2 		$4.42M Buy
15,329
+11
+0.1% +$3.24K ﹤0.01% 2813
2020
Q1 		$3.13M Buy
15,318
+566
+4% +$180K ﹤0.01% 2848
2019
Q4 		$6.59M Buy
14,752
+382
+3% +$136K ﹤0.01% 2716
2019
Q3 		$4.42M Buy
14,370
+2,404
+20% +$781K ﹤0.01% 2849
2019
Q2 		$3.81M Buy
11,966
+11,443
+2,188% +$3.96M ﹤0.01% 2966
2019
Q1 		$219K Buy
+523
New +$210K ﹤0.01% 3562
2017
Q2 		– Sell
-1,101
Closed -$379K – 3748
2017
Q1 		$379K Buy
1,101
+84
+8% +$28.9K ﹤0.01% 3422
2016
Q4 		$356K Buy
1,017
+124
+14% +$45.4K ﹤0.01% 3433
2016
Q3 		$357K Buy
893
+175
+24% +$89.3K ﹤0.01% 3342
2016
Q2 		$428K Buy
+718
New +$436K ﹤0.01% 3408
2014
Q2 		– Sell
-89
Closed -$480K – 3681
2014
Q1 		$480K Buy
+89
New +$421K ﹤0.01% 3368

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

State Street's EIGR Position: Q1 2024 in Review

State Street sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 4,893 shares — an estimated $33K sold.

State Street first reported a position in EIGR in Q1 2014 and held it in 25 quarters. The position peaked at $6.59M in Q4 2019. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • State Street reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • State Street sold 4,893 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $33K.
  • State Street first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 25 quarters.
  • State Street's Eiger BioPharmaceuticals, Inc. position peaked at $6.59M in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.